Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481816 | 1.00 | PPARG (0.54) | PPARGPPARASLC6A4CACNA2D1CETP | |
| SCHEMBL5481812 | 1.00 | PPARG (0.54) | PPARGPPARASLC6A4CACNA2D1CETP | |
| Hydrochloric Acid SCHEMBL5475519 | 0.99 | PPARG (0.52) | PPARGPPARASLC6A4CACNA2D1CETP | |
| Hydrochloric Acid SCHEMBL5475524 | 0.99 | PPARG (0.52) | PPARGPPARASLC6A4CACNA2D1CETP | |
| Hydrochloric Acid SCHEMBL5475527 | 0.99 | PPARG (0.52) | PPARGPPARASLC6A4CACNA2D1CETP | |
| SCHEMBL3991808 | 0.81 | PPARG (0.52) | PPARGPPARASLC6A4CETPRAB9A | |
| SCHEMBL5479117 | 0.80 | PPARG (0.57) | PPARGPPARASLC6A4CETPRAB9A | |
| SCHEMBL5481622 | 0.80 | PPARG (0.57) | PPARGPPARASLC6A4CETPRAB9A | |
| SCHEMBL5475463 | 0.79 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5475469 | 0.79 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072859-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY (US) | 2007-03-29 | — | — | US | claimed |
| EP-1725518-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005092835-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072859-A1 | Pharmaceutical compounds | ADRB3, HTR3C, SLC6A2 | PPARG 3659/4885PPARA 4023/4885SLC6A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.